期刊文献+

有机阴离子转运因子2的多态性与某省新生儿重症高胆红素血症的相关性研究 被引量:1

The Relevance of OATP2 Gene Mutation to the Severe Hyperbilirubinemia in Neonates in A Province
下载PDF
导出
摘要 目的探讨有机阴离子转运因子2(OATP2)的A388G及T521C基因多态性与云南省新生儿高胆红素血症的相关性。方法 180例新生儿重症高胆红素血症作为病例组,80例无黄疸新生儿作为对照组。采用常规方法提取DNA,用聚合酶链反应(PCR)方法扩增,琼脂糖凝胶电泳鉴定产物,PCR产物进行DNA测序。结果病例组与对照组A388G等位基因突变率分别为25%及23%,病例组A388G基因频率与对照组间差异无统计学意义(χ2=1.056,P>0.05);病例组与对照组T521C基因等位基因突变率分别为9%及3%,病例组T521C基因频率显著高于对照组,差异有统计学意义(χ2=5.590,P<0.05)。结论云南省重症新生儿高胆红素血症的发生与有机阴离子转运因子2的A388G基因突变无关,而与T521C基因的多态性密切相关。 Objective To investigate the relevance of OATP2 gene mutation in A388G and T521C to the severe hyperbilirubinemia in neonates in Yunnan.Methods The case group are 180 severe hyperbilirubinemia cases,the control group are 80 neonates without jaundice.Get out the DNA with routine;amplification gene with PCR;identify output with agarose gel electrophoresis;then sequencing.Results The case group and the control group allele gene frequency of A388G were 25%and23%,allele gene frequency in two group has not statistical difference(χ2=1.056,P0.05).the case group and the control group allele gene frequency of T521C were 9% and 3%,the case group allele gene frequency of T521C was significantly higher than the control group,the difference has statistical significance(χ2=5.590,P 0.05).Conclusions These results indicate that the severe hyperbilirubinemia in neonates is intimate correlate with T521C mutation,and independence with A388G mutation in Yunnan.
出处 《中国医药指南》 2012年第36期414-415,共2页 Guide of China Medicine
关键词 新生儿 有机阴离子转运因子 基因突变 高胆红素血症 Infant OATP2 Gene mutation Hyperbilirubinemia
  • 相关文献

参考文献9

  • 1孟强,刘克辛.转运体在肝脏中的作用[J].世界华人消化杂志,2011,19(9):881-886. 被引量:13
  • 2Zollner G,Trauner M. Mechanisms of cholestasis[J].Clinics in Liver Disease,2008,(01):1-26.
  • 3Huang MJ,Kua KE,Teng HC. Risk factors f or severe hyper-bilirubinemia in neonates[J].Pediatric Research,2004,(05):682-689.
  • 4Wong FL,Boo NY,Inoon A. Variants of organic anion transporter polypeptide 2 gene are not risk factors associated with severe neonatal hyperbilirubinemia[J].Malaysian J Pathol,2009,(02):99–104.
  • 5Tirone RG,LEeake BF,Merino G. Polymorphisms in OATP-C[J].J Biol Chemitry,2001,(28):35669-35675.
  • 6Leonhardt M,Keiser M,Oswald S. Hepatic uptake of the magnetic resonance imagingcontrast agent Gd-EOB-DTPA:role of humanorganic anion transporters[J].Drug Metabolism and Disposition,2010,(07):1024-1028.
  • 7Ho RH,Choi L,Lee W. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants[J].PHARMACOGENETICS AND GENOMICS,2007,(08):647–656.
  • 8Wang P,Kim RB,Chowdhury JR. The human organic anion transport protein SLC21A6 is not sufficient forbilirubin transport[J].Journal of Biological Chemistry,2003,(23):20695–20699.
  • 9Nozawa T,Nakajima M,Tamai I,et a1. Genetic Polymorphisms of Human Organic Anion Transporters OATP-C (SLC21 A6) and OATP-B (SLC21 A9):Allele Frequencies in the Japanese Population and Functional Analysis[J].Journal of Pharmacology and Experimental Therapeutics,2002,(02):804-813.

二级参考文献29

  • 1Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006; 27: 425-446.
  • 2Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, Trauner M. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003; 38: 717-727.
  • 3Kanda D, Takagi H, Kawahara Y, Yata Y, Takakusagi T, Hatanaka T, Yoshinaga T, Iesaki K, Kashiwabara K, Higuchi T, Mori M, Hirota T, Higuchi S, Ieiri I. Novel large-scale deletion (whole exon 7) in the ABCC2 gene in a patient with the Dubin-Johnson syndrome. Drug Metab Pharmacokinet 2009; 24: 464-468.
  • 4Jones PM, George AM. The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci 2004; 61: 682-699.
  • 5Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 2007; 24: 1803-1823.
  • 6Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 2006; 34: 1756-1763.
  • 7Sai Y, Tsuji A. Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discov Today 2004; 9: 712-720.
  • 8Kouzuki H, Suzuki H, Stieger B, Meier PJ, Sugiyama Y. Characterization of the transport properties of organic anion transporting polypeptide 1 (oatp1) and Na(+)/taurocholate cotransporting polypeptide (Ntcp): comparative studies on the inhibitory effect of their possible substrates in hepatocytes and cDNA-transfected COS-7 cells. J Pharmacol Exp Ther 2000; 292: 505-511.
  • 9Leonhardt M, Keiser M, Oswald S, Kühn J, Jia J, Grube M, Kroemer HK, Siegmund W, Weitschies W. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 2010; 38: 1024-1028.
  • 10Agarwal S, Pal D, Mitra AK. Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm 2007; 339: 139-147.

共引文献12

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部